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Verónica Brito and Silvia Ginés
Huntington’s disease (HD) is a fatal 
neurodegenerative disorder with a characteristic 
phenotype including chorea and dystonia, uncoordinated 
fine movements, cognitive decline and psychiatric 
disturbances. Even though the clinical diagnosis of HD 
relies on the manifestation of motor abnormalities, the 
associated memory impairments have been growing in 
prominence. Indeed, cognitive deficits are evident along 
all the disease process even in the prodrome before any 
motor diagnosis is given. 
These clinical signs have been mainly attributed to 
corticostriatal dysfunction being deficits of neurotrophic 
support, caused by either reduced levels of brain-derived 
neurotrophic factor (BDNF) [1] or decreased TrkB 
and aberrant p75NTR signalling [2, 3], one of the major 
pathogenic mechanism involved. However, in recent 
years has emerged the idea that cognitive decline in 
HD is likely a reflection of a widespread brain circuitry 
defect rather than a basal ganglia dysfunction per se. In 
this regard, in our recent studies we shed new light on the 
contribution of the hippocampal circuitry to synaptic and 
memory decline in HD. We demonstrated hippocampal 
dysfunction in a precise genetic HD mouse model that 
expresses endogenous levels of mutant huntingtin, HdhQ7/
Q111 mice, manifested as alterations in spatial, recognition 
and associative memories. 
To get insight into the molecular mechanisms 
underlying such defects, we focused on p75NTR since 
growing evidence indicate that p75NTR plays an 
antagonistic role in synaptic plasticity. We demonstrated 
up-regulation of p75NTR in the hippocampus of distinct 
HD mouse models and in human brain without evident 
changes in the cortex, which extends our previous data 
showing increased p75NTR expression in the HD striatum 
[4]. In agreement with a critical role of aberrant p75NTR 
expression in hippocampal dysfunction we found 
preserved spatial, recognition and associative memories in 
new double-mutant mice expressing mutant huntingtin but 
“physiological” levels of p75NTR levels (HdhQ7/Q111:p75+/- 
mice).
How aberrant p75NTR levels may mediate synaptic 
and memory deficits in HD is an intriguing question. On 
one hand, our results indicated that p75NTR directly or 
indirectly regulate the expression of different synaptic-
related proteins previously implicated in HD synaptic 
and/or cognitive deficits, such as CBP, CamKII, GluA1 
or BDNF since memory improvements in double mutant 
HdhQ7/Q111:p75+/- mice correlated with a recovery of the 
expression and/or phosphorylation of these molecules. On 
the other, the loss of dendritic spines in CA1 pyramidal 
neurons exhibited by HdhQ7/Q111 mutant mice was also 
prevented by normalization of p75NTR levels. Altogether, 
these data suggest that synaptic and memory deficits in 
HD could be related with a reduction in proteins involved 
in synaptic function and in the number and complexity of 
hippocampal dendritic spines in agreement with a role of 
p75NTR as a negative regulator of dendritic spine dynamics 
and synaptic activity.
We further built on work showing that 
p75NTRcontributes to synaptic dysfunction and memory 
decline in HD by deregulation of RhoA activity, a small 
GTPase with complex effects on spines and thereby 
in synaptic plasticity [5]. Interestingly, such increase 
was reversed in double mutant HdhQ7/Q111:p75+/- mice 
suggesting a direct link between aberrant p75NTR activity, 
dendritic spine loss and aberrant RhoA activity. In 
agreement with our findings Plotkin and colleagues [3] 
have demonstrated that plasticity in indirect pathway 
spiny projection neurons (iSPNs) from BACHD mutant 
mice can be rescued by inhibition of the p75NTR-RhoA 
signalling suggesting that early corticostriatal dysfunction 
in HD could also be attributable to a correctable defect 
in BDNF signalling. Altogether, this evidence strongly 
suggests that, in the early stages of the disease, p75NTR 
antagonism should be considered an effective therapeutic 
strategy for restoring BDNF neuroprotective and synaptic 
functions. However, remains to be investigated whether 
therapeutic approaches targeting p75NTR inhibition 
should also integrate TrkB activation to produce the most 
favourable benefits on motor and cognitive impairments. 
Moreover, we have recently demonstrated that 
fingolimod, a compound used as an immunomodulator 
in Multiple Sclerosis patients, restores hippocampal 
synaptic plasticity and improves memory function in 
a mouse model of Huntington disease acting through 
down-regulation of TNFα and p75NTR [6]. These last 
evidence open the question whether p75NTR dysregulation 
is triggered by neuroinflammation at very early stages 
and whether modulation of the inflammatory response 
of microglia and astroglia in HD may contribute to 
antagonize the deleterious effects of aberrant p75NTR-
induced RhoA activity in synaptic plasticity. So far, our 
studies strongly implicates p75NTR-RhoA hippocampal 
dysfunction on cognitive decline in HD stressing the 
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need to explore therapeutic strategies that target the 
identified pathways, not only in the striatum but also in 
other brain areas besides the basal ganglia which has been 
underestimated and are strongly involved in HD cognitive 
pathology
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